Trisomy 3 may predict a poor response of gastric MALT lymphoma to Helicobacter pylori eradication therapy

Table 1 Clinicopathological data of 13 patients with gastric MALT lymphoma.

Case No.	Sex/Age(yr)	Hp.	Endoscopic findings ＃	Depth	Response	Time for regression (mo)	Second therapy	Follow-up (mo)
1	M/72	(+)	SS	m	CR	8	(-)	105
2	F/69	(+)	SS	m	CR	2	(-)	81
3	F/73	(+)	SS	m	CR	1	(-)	41
4	F/55	(+)	SS	m	CR	6	(-)	30
5	F/60	(+)	SS	m2	CR	2.5	(-)	35
6	F/50	(+)	SS	m2	CR	1	(-)	26
7	M/72	(+)	SS	m2	CR	4	(-)	26
8	M/49	(-)	SS	Sm	PR	(-)	observation	49
9	M/71	(+)	SS	Sm	NR	(-)	observation	45
10	M/68	(+)	MF	Sm	NR	(-)	EMR	29
11	M/49	(+)	DI	Sm	NR	(-)	Ritsuximab→RT	23
12	F/59	(+)	MF	Sm1	PD	(-)	Gastrectomy	91
13	M/69	(+)	SS	Sm2	PD	(-)	CHOP	26

Abbreviations: SS, superficial spreading; MF, mass forming; DI, diffuse infiltrating; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; EMR, endoscopic mucosal resection. ¹Assessed by samples resected surgically; ²assessed by the endoscopic and gastrointestinal X ray examination.